PANCREATIC ADENOCARCINOMA

This early-stage study tests an experimental drug called SGN-MesoC2 in people with advanced solid tumors (like lung, ovarian, or pancreatic cancer) that have not responded to standard treatments. The drug is designed to attach to cancer cells and kill them. The main goals are to …

This study tests whether switching from one chemotherapy combination to another before surgery can help people with pancreatic cancer. It includes patients whose tumors can be removed or are borderline removable. The goal is to see if the switch leads to better surgical outcomes …

This early-phase study tests a new drug called LP-184 in 64 adults with advanced solid tumors (like pancreatic, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their …

This study tests an experimental oral drug called IMM-1-104 in people with advanced solid tumors that have RAS mutations. The goal is to find the best dose and see if it can shrink tumors or slow their growth. About 209 adults with pancreatic cancer, melanoma, or lung cancer will…

This study tests whether adding two experimental drugs (elraglusib and losartan) to standard chemotherapy (FOLFIRINOX) can prevent metastatic pancreatic cancer from becoming resistant to treatment. About 70 adults with untreated, advanced pancreatic cancer will receive the combin…

This study tests whether combining two drugs—atezolizumab (an immunotherapy) and tivozanib (a targeted therapy)—can shrink tumors in cancers that typically don't respond to immunotherapy alone. About 29 adults with advanced bile duct, gallbladder, breast, neuroendocrine, ovarian,…

This study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with advanced cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help control the cancer. About 350 people with various cancer types, …

This early-phase study tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The treatment pairs a targeted chemotherapy (anetumab ravtansine) with immunotherapy drugs (nivolumab, ipilimumab) and/or standard chemo (gemcit…

This early-phase study tested a new drug called sEphB4-HSA combined with standard chemotherapy in 61 people with advanced or metastatic solid tumors (like head and neck, pancreatic, lung, and gallbladder cancers). The goal was to find the best dose and check for side effects. Whi…

This study compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combination (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer that has spread to other parts of the body. Only patien…

This study tests a new device that places tiny alpha radiation seeds directly into pancreatic tumors. It includes 37 adults with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the procedure is safe and possible, and to check early signs of tum…

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This early-phase study tests a new treatment called EGFR-BATs for people with advanced pancreatic cancer that has not responded to standard chemotherapy. The treatment uses the patient's own immune cells, which are trained in a lab to better attack cancer cells. The main goal is …

This early-phase study tests an experimental drug called DECOY20, given alone or with another drug (tislelizumab), in about 120 adults with advanced solid tumors like liver, colorectal, pancreatic, lung, head and neck, bladder, or MSI-high cancers. The main goals are to check saf…

This study looks at whether adding a special pancreatic enzyme pill (Pancreaze) to usual treatment can help people with advanced pancreatic cancer who are losing weight and have trouble digesting food. About 36 adults with this condition will take the enzyme pills with meals and …

This early-phase study tests whether adding the diabetes drug metformin and a specific dietary supplement mix to standard chemotherapy is safe and feasible for people with pancreatic cancer that cannot be removed by surgery. The supplement includes ingredients like curcumin, vita…

This early-phase study tests a personalized vaccine made from a patient's own immune cells, combined with standard chemotherapy and an immunotherapy drug (nivolumab), for people with pancreatic cancer that was surgically removed. The goal is to see if this combination is safe and…

This study tests a combination of three chemotherapy drugs (liposomal irinotecan, 5-FU, and oxaliplatin) given before surgery to people with pancreatic cancer that can be removed. The goal is to see if this approach is safe and helps reduce complications after surgery. About 45 a…

This study tests whether adding the drug durvalumab to standard radiation therapy can help control locally advanced pancreatic cancer. About 18 people who have already received chemotherapy will receive the combination. The goal is to see if the treatment is safe and can shrink t…

This study is checking if a computer model called PRISM can accurately predict who might get pancreatic cancer by looking at electronic health records. Over 6 million adults aged 40 and older from across the US are being tracked to see if the model's risk scores match real cancer…

This study looks at whether a supervised, at-home resistance training program done via tablet is safe and helpful for people with advanced pancreatic cancer. About 25 participants will do guided exercises while receiving chemotherapy or recovering from surgery. The goal is to see…

This study looks at a new way to perform surgery for pancreatic cancer. The goal is to see if a special dissection technique around a key artery can help surgeons remove all cancer cells more often. About 100 adults with removable pancreatic tumors will take part, and the study w…

This study aims to create a test that uses circulating tumor cells to predict which chemotherapy regimen will work best for each person with advanced pancreatic cancer. Researchers will analyze tumor cells from 74 participants to see if the test can accurately forecast treatment …

This study tests two different drug combinations in people with advanced colorectal, pancreatic, or leiomyosarcoma cancers that have not responded to standard treatments. Participants receive either olaparib plus durvalumab or cediranib plus durvalumab. The main goal is to unders…